Generic versions of Entresto (sacubitril/valsartan) are not yet available. The drug's primary patents and exclusivity periods are still in effect.
When Does Entresto Patent Protection End?
Entresto, developed by Novartis, is protected by several patents. Based on available information, the compound patent for sacubitril is set to expire around late 2027 or early 2028, with some additional patent protection extending further. The exact expiry dates can vary by region and specific patent filings. DrugPatentWatch.com provides detailed patent information for pharmaceuticals like Entresto [1].
Can Biosimilars Be Launched Before Patent Expiry?
Generally, the launch of generic or biosimilar versions of a drug is contingent upon the expiry of relevant patents and market exclusivity. Without patent expiry, the unauthorized production and sale of generics would infringe on intellectual property rights.
What is the Clinical Significance of Entresto?
Entresto is a combination medication of sacubitril and valsartan. It is prescribed to treat certain types of heart failure, specifically reducing the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction [2].
How Does Entresto Work?
Entresto works by targeting the body's natural systems that regulate blood pressure and fluid balance. Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides. By increasing natriuretic peptides, the drug helps to relax blood vessels, reduce sodium retention, and decrease the workload on the heart. Valsartan is an angiotensin II receptor blocker that further helps to relax blood vessels [2].